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Abstract
Background: The 2010 guidelines of the French National Cancer Institute (INCa) classify patients with endometrial
cancer into three risk groups for lymph node invasion and recurrence on the basis of MRI and histological analysis
of an endometrial specimen obtained preoperatively. The classification guides therapeutic choices, which may
include pelvic and/or para-aortic lymphadenectomy. The purpose of this study was to evaluate the diagnostic
performance of preoperative assessment to help identify intermediate- or high-risk patients requiring
lymphadenectomy.
Methods: The study included all patients who underwent surgery for endometrial cancer between January 2010
and December 2013 at either Rennes University Hospital or Vannes Regional Hospital. The criteria for eligibility
included a preoperative assessment with MRI and histological examination of an endometrial sample. A histological
comparison was made between the preoperative and surgical specimens.
Results: Among the 91 patients who underwent a full preoperative assessment, the diagnosis of intermediate- or
high-risk endometrial cancer was established by MRI and histology with a sensitivity of 70 %, specificity of 82 %,
positive predictive value (PPV) of 87 %, negative predictive value (NPV) of 61 %, positive likelihood ratio (LR+) of 3.8
and negative likelihood ratio (LR-) of 0.3. The risk group was underestimated in 32 % of patients and overestimated
in 7 % of patients. MRI underestimated endometrial cancer stage in 20 % of cases, while endometrial sampling
underestimated the histological type in 4 % of cases and the grade in 9 % of cases.
Conclusion: The preoperative assessment overestimated or underestimated the risk of recurrence in nearly 40 % of
cases, with errors in lesion type, grade or stage. Erroneous preoperative risk assessment leads to suboptimal initial
surgical management of patients with endometrial cancer.
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Background
The FIGO (International Federation of Gynecology and
Obstetrics) classification of endometrial cancer and its
surgical management was reviewed in 2009–2010 [1].
The preoperative assessment recommended by the French
National Cancer Institute (INCa) includes MRI and histo-
logical examination of an endometrial sample obtained by
curettage with hysteroscopy or biopsy with a Cornier®
pipelle. The assessment determines the tumour stage,
histological type and grade for endometrioid (type I)
adenocarcinomas [1]. The aim of the preoperative assess-
ment is to classify patients into one of three risk groups
(low, intermediate or high) for lymph node invasion and
recurrence and to help guide surgical staging to determine
whether pelvic and/or para-aortic lymphadenectomy
should be performed [1–10]. Although no benefit for
lymphadenectomy was seen in patients with early low-risk
disease in two prospective randomised trials [11, 12],
lymph node status is a strong prognostic factor for guiding
the choice of adjuvant treatment [9, 13–18].
The preoperative evaluation of lymph node metastatic
risk based on MRI is poor because used criteria are
defective or incomplete [19–21]. For example, using MRI,
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myometrial involvement > 50 % is underestimated in 21 %
and 32 % of endometrioid grade 1 and grade 2 adenocar-
cinoma, respectively [22]. In the same way, the grade is
underestimated by preoperative biopsy or curettage in 20
to 25 % of preoperative endometrioid grade 1 adenocar-
cinoma [23]. Although this defective performance of each
tool assessing preoperative risk, little data are available
that evaluate combined MRI and preoperative biopsy to
assess endometrial cancer risk for lymph node invasion
and recurrence.
The aim of this study was to evaluate the combined
performance of MRI and histological analysis in predicting
the risk of lymph node invasion and recurrence. Used
preoperatively, the combined assessment can identify
which patients should undergo pelvic and/or para-aortic
lymphadenectomy as per the existing guidelines [1].
Methods
Design
This is a retrospective study of all patients who
underwent surgery for endometrial cancer between
1st January 2010 and 31st December 2013 at either
Rennes University Hospital or Vannes Regional Hospital
(by 5 general gynaecologic surgeons). The inclusion criter-
ion was evidence of endometrial cancer of any type, grade
or stage as confirmed by a preoperative endometrial
sample or hysterectomy specimen. The exclusion criteria
were lack of preoperative data concerning the type and
grade (determined by endometrial sampling) or FIGO
stage (determined by MRI). The research protocol was
approved by the Institutional Review Board of the French
College of Obstetrics and Gynaecology (CEROG 2014-
GYN-020).
Data collection
The following data were collected for all patients: patient
characteristics (age, BMI, menopausal status, use of hor-
mone replacement therapy for the menopause), surgical
treatment (type of procedure, approach), adjuvant treat-
ment, preoperative radiology and histology results, as
well as final histology.
The preoperative MRI was performed following
European Society of Urogenital Imaging guidelines [24].
The data required for FIGO 2009 staging (degree of
myometrial, cervical, adnexal and serosal invasion, posi-
tive pelvic or para-aortic lymph nodes greater than
10 mm in size) were also collected. The data collected
from the preoperative histology report were tumour type
and grade for endometrioid tumours (type 1) and the
method used: Cornier® pipelle (an outpatient procedure)
or curettage with hysteroscopy (performed in the operat-
ing theatre). Following final analysis of the surgical
specimen, the type, grade, presence of lymphovascular
emboli and FIGO 2009 stage were recorded.
Definition of risk levels for lymph node invasion
Type 1 tumours consisted of endometrioid adenocarcin-
omas and mixed tumours with a mucinous or villoglandu-
lar component in addition to the endometrioid component.
For these tumours, histological grade was defined by the
percentage of the undifferentiated component: grade 1
corresponded to an undifferentiated component of less
than 5 %, grade 2 from 6 to 50 % and grade 3 more than
50 %. When nuclear atypia was marked, the grade was in-
creased by 1 point [1].
Type 2 tumours were those with at least one serous,
clear cell or carcinosarcoma component. Tumours that
Fig. 1 Flow chart
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were completely undifferentiated or whose type could
not be determined were classified as type 2.
In both the preoperative and postoperative periods, on
the basis of their FIGO 2009 stage, type and grade the
tumours were classified into recurrence risk groups as
defined in the European Society for Medical Oncology
(ESMO) guidelines [5, 6]. The three risks groups were
determined as follows: low risk – stage IA, grade 1 or 2,
histological type 1; intermediate risk – stage IA, grade 3
and stage IB, grade 1 or 2, histological type 1; high risk
– stage IB, grade 3 and, by extension, stage ≥ II, histo-
logical type 1, as well as all type 2 tumours of any stage
and tumours of any type or stage with lymphovascular
emboli, as per French guidelines [1].
Outcome measure
The primary endpoint was the risk group (low, inter-
mediate or high). Secondary endpoints were FIGO stage,
myometrial, cervical and lymph node involvement as
well as tumour type and grade.
Statistical analysis
The results of the preoperative assessment were com-
pared with the final histological analysis of the surgical
specimen. For type and grade assessment, the perform-
ance of the Cornier® pipelle and curettage with hysteros-
copy was compared.
The sensitivity, specificity, PPV, NPV, LR+ and LR- of
the preoperative assessment were calculated for each end-
point, together with 95 % confidence intervals (95 % CI).
The percentage of underestimation or overestimation and
accuracy rate were also calculated. The higher the LR+,
the more useful the positive result of an examination
proved to be. The examination was deemed useful when
its LR+ was greater than 5. The closer the LR- was to 0,
the more useful the negative result of the examination
proved to be [1].
The χ2 test or Fisher’s exact test were used to compare
categorical variables as appropriate. Results were consid-
ered significant when the p value was less than 0.05. All
data were collected in an Excel database (Microsoft,
Redmond, WA, USA) and analysed using R Core Team
(2013) statistical software (R Foundation for Statistical
Computing, Vienna, Austria; www.R-project.org).
Results
The study identified 150 patients who had undergone
surgery for endometrial cancer between 2010 and 2013:
99 (66.0 %) at Rennes University Hospital and 51
(34.0 %) at Vannes Regional Hospital.
Fifty-nine patients (39.3 %) were excluded for incom-
plete preoperative assessment data due to at least one of
the following reasons: use of an imaging technique other
than MRI (ultrasound, PET or CT scan) (n = 46), degree
Table 1 Characteristics of included patients (n = 91)
Variable n /%
Agea median and interval, in years 67 (38–90)
BMIa median and interval in kg/m2 29.96 (19.23–53.83)
Menopausea 82 (90.11 %)
Hormonal treatment for the menopausea 26 (28.57 %)
Preoperative endometrial sample
Curettage 44 (48.35 %)
Pipelle 47 (51.64 %)
Surgery performeda
Total hysterectomy with BSO 87 (95.60 %)
Total hysterectomy 4 (4.40 %)
Surgical approacha
Laparotomy 23 (25.27 %)
Laparoscopy 64 (70.33 %)
Vaginal 4 (4.40 %)
Lymphadenectomya
No 37 (40.66 %)
Pelvic 36 (39.56 %)
Pelvic + sentinel lymph node 3 (3.30 %)
Pelvic + para-aortic 13 (14.29 %)
Sentinel lymph node 2 (2.20 %)
Final histology resultsa
FIGO stage (2009)a
IA 45 (49.45 %)
IB 21 (23.08 %)
II 13 (14.29 %)
IIIA 2 (2.20 %)
IIIB 1 (1.10 %)
IIIIC 7 (7.69 %)
IV 2 (2.20 %)
Histological typea
Type 1 78 (85.71 %)
Grade 1 46 (50.55 %)
Grade 2 20 (21.98 %)
Grade 3 12 (13.19 %)
Type 2 11 (12.09 %)
Absence of residual malignant cells 2 (2.20 %)
Lymphovascular embolia 32 (35.16 %)
Risk of recurrencea
Low 33 (36.26 %)
Intermediate 14 (15.38 %)
High 44 (48.35 %)
BSO bilateral salpingo-oophorectomy
a There was no significant difference between the pipelle group and the
curettage group
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of myometrial invasion not specified on the MRI and
images not available for review (n = 7), chance discovery
of cancer in the surgical specimen (n = 9), type or grade
not specified on the preoperative histology report and
slides not available for review (n = 11).
Ninety-one patients with endometrial cancer who had
undergone a complete preoperative assessment (MRI to
determine FIGO stage and histology to determine type
and grade for type 1 tumours), were finally included in
the study (Fig. 1).
The clinical and pathological characteristics of the
patients are provided in Table 1.
Histological analysis
Table 2 compares the pre- and postoperative histological
type.
Of 80 patients with type 1 cancer (endometrioid)
preoperatively, 4 (5.0 %) were reclassified as having type 2
cancer on final histological analysis. Conversely, of the 11
patients with type 2 cancer preoperatively, 4 (36.3 %) were
reclassified as having type 1 cancer on final histological
analysis. For the diagnosis of type 2 tumours, regardless of
the technique used the endometrial sample had sensitivity
of 63.6 % [95 % CI 35.4–84.8], specificity of 95 % [95 % CI
87.8–98.0], PPV of 63.6 % [95 % CI 35.4–84.8], NPV of
95 % [95 % CI of 87.8–98.0], LR+ of 12.7 [95 % CI 4.4–
36.5] and LR- of 0.4 [95 % CI 0.1–0.8]. Regardless of the
technique used, the endometrial sample correctly predicted
the histological type in 89.0 % of cases, overestimated it in
6.6 % of cases and underestimated it in 4.4 % of cases
(Table 3).
The endometrial sample was taken with a Cornier®
pipelle in 47 patients (51.6 %) and by curettage in 44
patients (48.3 %). Diagnostic performance for type 2
tumours is provided in Table 3. No significant differ-
ence was observed between the two techniques for
diagnosis of histological type.
The diagnostic performance of grading was assessed in
the 74 patients with a tumour diagnosed preoperatively as
type 1 and confirmed postoperatively. Regarding endome-
trioid tumours, for the diagnosis of grade 3 tumours the
endometrial sample had a sensitivity of 30.0 % [95 % CI
10.8–60.3], specificity of 98.4 % [95 % CI 91.7–99.7], PPV
of 75.0 [95 % CI 30.1–95.4], NPV of 90.0 % [95 % CI
80.8–95.1], LR+ of 19.2 [95 % CI 2.2–166.9] and LR- of
0.7 [95 % CI 0.4–1.1]. Endometrial sampling correctly pre-
dicted the grade for type 1 tumours in 89.2 % of cases,
overestimated it in 1.3 % of cases, and underestimated it
in 9.5 % of cases (Table 4).
The performance of the pipelle and curettage for diag-
nosing grade 3 tumours among endometrioid tumours is
provided in Table 4. There was no significant difference
between the two sampling techniques for establishing
the grade.
Lymphovascular emboli were found in 32 out of 91
patients (35.3 %) on histological analysis of the hysterec-
tomy specimen. Emboli were detected in 20 % of stage
IA, 38 % of stage IB, 38 % of stage II, 80 % of stage III
and 100 % of stage IV tumours regardless of type.
MRI analysis
The performance of the preoperative MRI for diagnosing
lymph node, cervical and myometrial invasion is reported
in Table 5. The degree of myometrial invasion was under-
estimated in 11.4 % of cases, accurate in 81.8 % of cases
and overestimated in 6.8 % of cases. Cervical invasion was
underestimated in 10.9 % of cases, accurate in 89.0 % of
cases and never overestimated. Fifty-two of the 91 patients
(57.1 %) underwent pelvic lymphadenectomy with para-
aortic lymphadenectomy in 13 cases (14.3 %). Among
these 52 patients, lymph node status was underestimated
in 3.8 % of cases, accurate in 78.8 % of cases and overesti-
mated in 17.3 % of cases.
For the diagnosis of FIGO stages > IA, MRI had a sensi-
tivity of 78.3 % [95 % CI 64.4–87.7], specificity of 88.9 %
[95 % CI 76.5–95.2], PPV of 87.8 % [95 % CI 74.5–94.7],
NPV of 80.0 % [95 % CI 67.0–88.8], LR+ of 7.0 [95 % CI
3.0–16.3] and LR- of 0.2 [95 % CI 0.1–0.4] (Table 6).
For the diagnosis of FIGO stages > IB, MRI had a sensi-
tivity of 60.0 % [95 % CI 40.7-76.6], specificity of 93.9 %
[95 % CI 85.4–97.6], PPV of 78.9 % [95 % CI 56.7–91.5],
Table 2 Histological type of endometrial cancers: comparison of
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NPV of 86.1 % [95 % CI 76.3–92.3], LR+ of 9.9 [95 % CI
3.6–26.9] and LR- of 0.4 [95 % CI 0.2–0.6].
FIGO stages IA, IB, II, III and IV considered individually
were underestimated in 20.9 % of cases, accurate in 65.9 %
of cases and overestimated in 13.2 % of cases (Fig. 2).
Performance of the preoperative assessment for
determining risk
For diagnosing intermediate- or high-risk endometrial
cancer, the preoperative combination of MRI and hist-
ology had a sensitivity of 70.0 % [95 % CI 58.0–80.8],
specificity of 81.8 % [95 % CI 65.6–91.4], PPV of 87.2 %
[95 % CI 74.8–94.0], NPV of 61.4 % [95 % CI 46.6–74.3],
LR+ of 3.8 [95 % CI 1.8–8.2] and LR- of 0.3 [95 % CI
0.2–0.5] (Table 6).
Considered independently, the risk groups (low, inter-
mediate and high) were underestimated in 31.9 % of
cases, accurate in 60.4 % of cases and overestimated in
7.7 % of cases.
In practice, if we consider only the 23 patients who
were in the low- or intermediate-risk group preopera-
tively but reclassified as high risk on final histology, the
error was due to grade underestimation in 3 cases (14.2 %),
underestimation of FIGO stage in 9 cases (42.8 %) and
presence of emboli in 11 cases (47.8 %).
Among the 37 patients with type 1, grade 1–2, stage
IA adenocarcinoma on final analysis, 6 (16.2 %) were
classified in the high-risk group owing to the presence of
emboli. Similarly, among the 22 patients with type 1
grade 3 stage IA adenocarcinoma or grade 1–2 stage IB
adenocarcinoma, 8 (36.4 %) were classified in the high-
risk group due to the presence of emboli (Fig. 3).
Surgical management according to risk group
In terms of surgical management, pelvic lymphadenec-
tomy was not performed despite being considered in 6 pa-
tients classified in the intermediate- rather than low-risk
group. Thirteen patients underwent pelvic lymphadenec-
tomy only despite para-aortic lymphadenectomy also be-
ing recommended following final analysis. Ten patients
did not undergo lymphadenectomy despite pelvic lymph-
adenectomy being recommended. Among these 23
patients, only 2 underwent a new procedure (one patient
in the intermediate-risk group and one in the high-risk
group) involving pelvic lymphadenectomy. No tumour in-
vasion was observed in either case.
Table 3 Diagnosis of type 2 endometrial cancers by preoperative endometrial sample (n = 91)
Cornier® Pipelle (n = 47) Curettage with hysteroscopy (n = 44) Both types of sampling (n = 91)
Sensitivity (%) [95 % CI] 60.0 [23.1–88.2] 66.7 [30.0–90.3] 63.6 [35.4–84.8]
Specificity (%) [95 % CI] 97.6 [87.7–99.6] 92.1 [79.2–97.3] 95.0 [87.8–98.0]
PPV (%) [95 % CI] 75.0 [30.1–95.4] 57.1 [25.0–84.2] 63.6 [35.4–84.8]
NPV (%) [95 % CI] 95.3 [84.5–98.7] 94.6 [82.3–98.5] 95.0 [87.8–98.0]
+LR [95 % CI] 25.2 [3.2–198.6] 8.4 [2.5–28.7] 12.7 [4.4–36.5]
-LR [95 % CI] 0.4 [0.14–1.2] 0.4 [0.1–1.1] 0.4 [0.1–0.8]
Overestimation (%) 2.1 * 11.4* 6.6
Accuracy rate (%) 93.6* 84.1* 89.0
Underestimation (%) 4.3* 4.5* 4.4
PPV positive predictive value, NPV negative predictive value, +LR positive likelihood ratio, −LR negative likelihood ratio
*There was no significant difference between the pipelle group and the curettage group (p = 0.259)
Table 4 Diagnosis of grade 3 endometrial cancers, among endometrioid-type cancers, by preoperative endometrial sample (n = 74)
Cornier® Pipelle (n = 41) Curettage with hysteroscopy (n = 33) Both types of sampling (n = 74)
Sensitivity (%) [95 % CI] 28.6 [8.2–64.1] 33.3 [6.1–79.2] 30.0 [10.8–60.3]
Specificity (%) [95 % CI] 97.1 [85.1–99.5] 100 [88.6–100] 98.4 [91.7–99.7]
PPV (%) [95 % CI] 66.7 [20.8–93.9] 100 [20.7–100] 75.0 [30.1–95.4]
NPV(%) [95 % CI] 86.8 [72.7–94.2] 93.7 [79.9–98.3] 90.0 [80.8–95.1]
+LR [95 % CI] 9.7 [1.0–92.9] NA 19.2 [2.2–166.9]
-LR [95 % CI] 0.7 [0.5–1.2] NA 0.7 [0.4–1.1]
Overestimation (%) 2.4* 0.0* 1.3
Accuracy rate (%) 85.4* 93.9* 89.2
Underestimation (%) 12.2* 6.1* 9.5
PPV positive predictive value, NPV negative predictive value, +LR positive likelihood ratio, −LR negative likelihood ratio, NA not applicable
*There was no significant difference between the pipelle group and the curettage group (p = 0.555)
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Discussion
Our study showed that MRI underestimated the stage of
endometrial cancer in 20 % of cases, and that endomet-
rial sampling underestimated the type and grade in 4 %
and 9 % of cases respectively. The combination of these
two preoperative investigations does not compensate for
any underestimation that may occur at an individual
level. The risk group for lymph node invasion was
underestimated in 31.9 % of patients, leading to surgical
understaging with incomplete or no lymphadenectomy
performed in 30.7 % of patients treated for endometrial
cancer.
The limitations of our study are those inherent to its
retrospective design: loss of data and selection bias. In-
terobserver variability in MRI and histology slide ana-
lysis can impair diagnostic performance. However our
results are consistent with the literature [9, 25]. Several
authors have studied the correlation between preopera-
tive and final histology [9, 22, 25–32]. In terms of deter-
mining the tumour type, these studies report an accuracy
rate of 74 % to 92 % [9, 28], with no significant difference
between the different sampling techniques, a finding com-
parable to our own results. In terms of determining the
grade, these studies report an accuracy rate of 44 % to
94 % [9, 22, 25, 28, 29], with no significant difference
between the different sampling techniques either, a finding
comparable to our own results [22, 25, 26, 28, 29]. Simi-
larly, numerous authors have addressed the diagnostic
performance of MRI for evaluating the degree of myome-
trial, cervical and nodal invasion [21, 33–37]. The results
of our study are comparable to those in the literature
[9, 25, 29, 37–42] which reports an accuracy rate of
between 66 % and 90 % and a positive likelihood
ratio >5 for evaluation of the degree of myometrial inva-
sion [1]. Few studies have specifically evaluated the per-
formance of MRI for FIGO staging, which is a composite
criterion [9, 40, 42]. Raimond et al. [9] reported a modest
performance with MRI for determining FIGO stage and a
30 % underestimation rate, consistent with the 20 %
underestimation rate observed in our study. Their findings
are similar to those of our study and confirm that the pre-
operative assessment performs better for more advanced
and therefore higher risk stages. When predicting FIGO
stage, overestimation by MRI is only 13 % in both our
studies.
The concept of risk groups was introduced after 2000
[2, 5, 6, 13, 14, 43, 44] to estimate the risk of lymph
node invasion and, over the longer term, recurrence, in
early stage disease. The study by Bendifallah et al. [2]
analysed the usefulness of different risk-group stratifica-
tion models and concluded that none of the models was
ideal for predicting recurrence and lymph node invasion.
Table 5 Diagnosis of deepness invasion of endometrial cancers by preoperative MRI (n = 91)
Cervical invasion (n = 91) Myometrial invasion ≥50 % (n = 91) Lymph node invasion (n = 52)
Sensitivity (%) [95 % CI] 23.1 [8.2–50.3] 73.7 [58.0–85.0] 71.4 [35.9–91.8]
Specificity (%) [95 % CI] 100 [95.3–100] 88.0 [76.2–94.4] 80.0 [66.2–89.1]
PPV (%) [95 % CI] 100 [43.8–100] 82.4 [66.5–91.7] 35.7 [16.3–61.2]
NPV (%) [95 % CI] 88.6 [80.3–93.7] 81.5 [69.2–89.6] 94.7 [82.7–98.5]
+LR [95 % CI] NA 6.1 [2.8–13.3] 3.6 [1.7–7.6]
-LR [95 % CI] NA 0.3 [0.2–0.5] 0.4 [0.1–1.6]
Overestimation (%) 0 6.8 17.3
Accuracy rate (%) 89.1 81.8 78.8
Underestimation (%) 10.9 11.4 3.8
PPV positive predictive value, NPV negative predictive value, +LR positive likelihood ratio, −LR negative likelihood ratio, NA not applicable
Table 6 Diagnosis of intermediate- and/or high-risk endometrial cancers by preoperative assessment (MRI and endometrial
sample) (n = 91)
Endometrial sample MRI Combination (MRI and histology)
Type 2 Grade 3 FIGO Stage > IA High risk Intermediate and high risk
Sensitivity (%) [95 % CI] 63.6 [35.4–84.8] 30.0 [10.8–60.3] 78.3 [64.4–87.7] 47.7 [33.8–62.1] 70.0 [58.0–80.8]
Specificity (%) [95 % CI] 95.0 [87.8–98.0] 98.4 [91.7–99.7] 88.9 [76.5–95.2] 93.6 [82.8–97.8] 81.8 [65.6–91.4]
PPV (%) [95 % CI] 63.6 [35.4–84.8] 75.0 [30.1–95.4] 87.8 [74.5–94.7] 87.5 [69.0–95.7] 87.2 [74.8–94.0]
NPV (%) [95 % CI] 95.0 [87.8–98.0] 90.0 [80.8–95.1] 80.0 [67.0–88.8] 65.7 [53.7–75.9] 61.4 [46.6–74.3]
+LR [95 % CI] 12.7 [4.4–36.5] 19.2 [2.2–166.9] 7.0 [3.0–16.3] 7.5 [2.4–23.3] 3.8 [1.8–8.2]
-LR [95 % CI] 0.4 [0.1–0.8] 0.7 [0.4–1.1] 0.2 [0.1–0.4] 0.6 [0.4–0.7] 0.3 [0.2–0.5]
PPV positive predictive value, NPV negative predictive value, +LR positive likelihood ratio, −LR negative likelihood ratio
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However risk stratification is still used to guide surgi-
cal management, and in particular the decision on
whether or not to perform pelvic and/or para-aortic
lymphadenectomy during total hysterectomy with
bilateral salpingo-oophorectomy. Several stratification
systems have been proposed, based on proven risk
factors such as type, grade and stage, but also age
and presence of lymphovascular emboli [2–7, 31, 45–48].
The latter criterion is an independent prognostic factor
correlated with the risk of lymph node involvement and
survival [31, 43, 46, 49, 50]. The 5-year overall survival
rate for patients with emboli, of any stage, is 64 % as com-
pared to 88 % for patients without emboli [5, 6]. Lympho-
vascular emboli should be considered in the risk
prediction process to guide endometrial cancer manage-
ment decisions. The inclusion of lymphovascular emboli
in the risk prediction equation was responsible for half the
cases of underestimation in our study — a finding
consistent with the literature [51]. The underestimation is
completely understandable given that emboli were found
in 35 % of cases on final histological analysis of the surgi-
cal specimen and that they are undetected by preoperative
histology. As shown by Hirschowitz et al., emboli are
visible in the myometrium surrounding the tumour area
but not in the tumour itself where tissue retraction is a
source of confusion [31]. There has been no study on the
possibility of detecting emboli preoperatively to date.
Our study and a previous one [2] show that the different
models for stratification into risk groups for lymph node
invasion are not useful for preoperative classification of
patients. Lymphadenectomy is therefore not performed at
the time of hysterectomy for 30 % of patients with endo-
metrial cancer. The risk of overestimating the risk, i.e.
performing an unnecessary lymphadenectomy, is low
(estimated at 13 % in our series in agreement with the
literature). Even if a preoperative assessment consisting of
Fig. 2 Pre and post operative assessment of FIGO stage. For the diagnosis of FIGO stages > IB, MRI had a sensitivity of 60.0 % [95 % CI
40.7–76.6], specificity of 93.9 % [95 % CI 85.4–97.6], Positive Predictive Value of 78.9 % [95 % CI 56.7–91.5], Negative Predictive Value of
86.1 % [95 % CI 76.3–92.3]
Fig. 3 Pre and post operative assessment of risk. For diagnosing intermediate- or high-risk endometrial cancer, the preoperative combination of
MRI and histology had a sensitivity of 70.0 % [95 % CI 58.0–80.8], specificity of 81.8 % [95 % CI 65.6–91.4], Predictive Positive Value of 87.2 % [95 %
CI 74.8–94.0], Negative Predictive Value of 61.4 % [95 % CI 46.6–74.3]. 0 low risk, 1: intermediate risk, 2: high risk, 3 very high risk
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MRI and histology is not useful for estimating the risk of
lymph node invasion, histological evaluation of lymph
nodes is still considered desirable for patients with endo-
metrial cancer who are classified as low-risk. To limit the
morbidity associated with routine lymphadenectomy in
patients with low-risk endometrial cancer, the sentinel
lymph node technique may offer a useful alternative.
Conclusion
The ESMO and of INCa guidelines propose therapeutic
de-escalation for the management of endometrial cancer.
Lymphadenectomy is not offered for low-risk endometrial
cancer [1, 5, 6, 9]. However in patients with endometrial
cancer classified as low-risk, risk stratification errors are
observed on preoperative assessment, with underestima-
tion occurring in at least 30 % of patients. Conversely,
preoperative risk overestimation is low. In conclusion, in
patients with endometrial cancer classified as low-risk as
determined by a preoperative assessment consisting of
MRI and endometrial sampling, histological examination
of lymph nodes still proves useful. The sentinel lymph
node technique could be used to limit the morbidity
associated with routine lymphadenectomy and could be
used routinely in patients with preoperative low risk
endometrial cancer because of poor performance of pre-
operative assessment of combined MRI and endometrial
sampling [21, 41, 52–60].
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